Abstract:3103 Background: Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disease characterized by elevated RAS-mitogen activated protein kinase (MAPK) signaling that causes tumors to grow along the nerves. There is currently no medical cure for adult patients (pts). Plexiform neurofibromas (PN) is present in 20-50% of NF1 pts and may cause serious complications. FCN-159 is a highly potent anti-tumorigenic agent that functions via selective inhibition of MEK1/2. This study assessed the safety and efficacy of FCN-159 in adult NF1 pts with PN. Methods: This was a multi-center, open-label, single-arm phase 1 dose-escalation (data have been published in ASCO 2022, abstract no. 3011) and phase 2 dose-expansion study. Participants with NF1-related PN that was not completely resectable or not suitable for surgery were enrolled in the study to receive FCN-159 monotherapy continuously on a 28-day cycles. Herein, we report the safety and clinical efficacy of adult participants in both phase 1 and phase 2. Results: As of November 21, 2022, 82 pts were enrolled, including 19 pts in phase 1 and 63 pts in phase 2. The median follow-up was 10.2 months (range 9.4-11.0 months) at the data cut-off. All pts received more than one dose of FCN-159 and 78 had at least one tumor assessment based on REiNS critiera. A total of 26 (33%) pts had achieved partial response (PR) as best response, 51 (65%) pts had stable disease (SD), and only one pt was not evaluable for not meeting the minimum SD requirement of at least 16 weeks. The overall response rate (ORR) was 31.7% (95% CI: 21.9-42.9%). After 6-8 cycles of treatment, 68.2% (15/22) of pts with definite tumor pain (NRS-11 score≥2 points) at baseline had a decrease in pain intensity of at least 2 points at C7/C9 assessment. Pain scores decreased by an average of 2.7 points across all 22 pts. A total of 82 (100%) pts experienced treatment emergent adverse events (TEAEs). The most common TEAEs (≥ 20%) included folliculitis (69.5%), mouth ulcer (47.6%), diarrhea (41.5%), paronychia (41.5%), alopecia (32.9%), elevated lactate dehydrogenase (30.5%), elevated alkaline phosphatase (29.3%), tricuspid insufficiency (26.8%), and mitral insufficiency (26.8%). The most common grade ≥3 TEAEs were folliculitis (25.6%), paronychia (4.9%). There were no grade ≥ 4 treatment-related adverse events. One pt (1.2%) experienced a serious adverse event (duodenal ulcer) considered related to the study drug. 9.8% reported TEAEs leading to dose reductions, and 12.2% reported TEAEs leading to discontinuation. No death occurred during the study. Conclusions: Overall, FCN-159 has a manageable safety profile and demonstrated evidence of anti-tumor activity in the adult population with NF1-related PN. These promising findings warrant further investigation with long-time follow-up. Clinical trial information: NCT04954001 .

Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas

Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials

Cognition and behavior in adults with neurofibromatosis type 1

Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study

Understanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM)

Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1

The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1

A multicenter, open-label, single-arm, phase 1 dose-escalation and phase 2 dose-expansion study to evaluate the safety, tolerability, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1.

The Lack of Ad Hoc Neuropsychological Assessment in Adults with Neurofibromatosis: A Systematic Review

A Systematic Review of Diagnostic Modalities and Strategies for the Assessment of Complications in Adult Patients with Neurofibromatosis Type 1

Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey

Satisfaction from surgical treatment and its influence on the wellbeing of patients with Recklinghausen disease - preliminary report

Family Reflections: Neurofibromatosis and our family perspective

Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1

Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas

Maintaining Engagement in Adults with Neurofibromatosis Type 1 to Use the iCanCope Mobile Application (iCanCope-NF)

Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1

NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY

Global research trends in cutaneous neurofibromas: A bibliometric analysis from 2003 to 2022

Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review